2-chloro-9-cyclopentyl-N-[2-(3-imidazol-1-ylpropoxy)phenyl]purin-6-amine | 1026001-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-chloro-9-cyclopentyl-N-[2-(3-imidazol-1-ylpropoxy)phenyl]purin-6-amine
• CAS: 1026001-88-6
• 化学式: C₂₂H₂₄ClN₇O
• 分子量: 437.932
• InChiKey: BLXNURGSNSCHGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  82.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  氰化钠 、 2-chloro-9-cyclopentyl-N-[2-(3-imidazol-1-ylpropoxy)phenyl]purin-6-amine 在 2,4-滴二甲胺盐 作用下， 生成 9-Cyclopentyl-6-[2-(3-imidazol-1-YL-propoxy)-phenylamino]-9H-purine-2-carbonitrile
  参考文献：
  名称：

  Novel Purine Nitrile Derived Inhibitors of the Cysteine Protease Cathepsin K

  摘要：

  Starting from the high-throughput screening hit la, novel cathepsin K inhibitors have been developed based on a purine scaffold. High-resolution X-ray structures of several derivatives have revealed the binding mode of these unique cysteine protease inhibitors.

  DOI：

  10.1021/jm0493111
• 作为产物：
  描述：

  2-[[4-(2-Chloroethoxy)phenyl]methoxy]aniline 在 potassium carbonate 作用下， 以 戊醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-chloro-9-cyclopentyl-N-[2-(3-imidazol-1-ylpropoxy)phenyl]purin-6-amine
  参考文献：
  名称：

  Novel Purine Nitrile Derived Inhibitors of the Cysteine Protease Cathepsin K

  摘要：

  Starting from the high-throughput screening hit la, novel cathepsin K inhibitors have been developed based on a purine scaffold. High-resolution X-ray structures of several derivatives have revealed the binding mode of these unique cysteine protease inhibitors.

  DOI：

  10.1021/jm0493111

文献信息

• Novel Purine Nitrile Derived Inhibitors of the Cysteine Protease Cathepsin K
  作者：Eva Altmann、Sandra W. Cowan-Jacob、Martin Missbach

  DOI：10.1021/jm0493111

  日期：2004.11.1

  Starting from the high-throughput screening hit la, novel cathepsin K inhibitors have been developed based on a purine scaffold. High-resolution X-ray structures of several derivatives have revealed the binding mode of these unique cysteine protease inhibitors.